EMEA-001214-PIP08-21
Key facts
| Invented name |
Fasenra
|
| Active substance |
Benralizumab
|
| Therapeutic area |
Pneumology-allergology
|
| Decision number |
P/0497/2021
|
| PIP number |
EMEA-001214-PIP08-21
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Treatment of non-cystic fibrosis bronchiectasis with an eosinophilic phenotype
|
| Route(s) of administration |
Subcutaneous use
|
| Contact for public enquiries |
AstraZeneca AB (Sweden)
Tel. +46 855326000 |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|